- Home
- HOWL vs OMGA Comparison
HOWL vs OMGA Comparison
Compare HOWL & OMGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- OMGA
- Stock Information
- Founded
- HOWL 2017
- OMGA 2017
- Country
- HOWL United States
- OMGA United States
- Employees
- HOWL N/A
- OMGA N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- OMGA Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- OMGA Health Care
- Exchange
- HOWL Nasdaq
- OMGA Nasdaq
- Market Cap
- HOWL 87.4M
- OMGA 74.5M
- IPO Year
- HOWL 2021
- OMGA 2021
- Fundamental
- Price
- HOWL $1.79
- OMGA $0.78
- Analyst Decision
- HOWL Strong Buy
- OMGA Strong Buy
- Analyst Count
- HOWL 2
- OMGA 5
- Target Price
- HOWL $13.50
- OMGA $9.20
- AVG Volume (30 Days)
- HOWL 656.6K
- OMGA 335.3K
- Earning Date
- HOWL 11-07-2024
- OMGA 11-14-2024
- Dividend Yield
- HOWL N/A
- OMGA N/A
- EPS Growth
- HOWL N/A
- OMGA N/A
- EPS
- HOWL N/A
- OMGA N/A
- Revenue
- HOWL $3,386,000.00
- OMGA $8,095,000.00
- Revenue This Year
- HOWL N/A
- OMGA $127.25
- Revenue Next Year
- HOWL $191.98
- OMGA N/A
- P/E Ratio
- HOWL N/A
- OMGA N/A
- Revenue Growth
- HOWL N/A
- OMGA 185.04
- 52 Week Low
- HOWL $1.58
- OMGA $0.75
- 52 Week High
- HOWL $8.19
- OMGA $6.30
- Technical
- Relative Strength Index (RSI)
- HOWL 32.55
- OMGA 31.99
- Support Level
- HOWL $1.58
- OMGA $1.06
- Resistance Level
- HOWL $2.24
- OMGA $1.17
- Average True Range (ATR)
- HOWL 0.16
- OMGA 0.10
- MACD
- HOWL -0.09
- OMGA -0.04
- Stochastic Oscillator
- HOWL 7.01
- OMGA 5.65
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About OMGA Omega Therapeutics Inc.
Omega Therapeutics Inc is a development-stage biotechnology company leveraging its proprietary epigenomic programming platform to biologically engineer a new class of programmable epigenetic medicines, known as Omega Epigenomic Controllers. Using epigenomic controllers, Omega is seeking to transform the practice of human medicine through selective and direct control of the human genome to treat and cure disease. It operates in the U.S.